Instructional video for preparation and administration of the coformulated subcutaneous formulation of daratumumab, aslo known as DARA-SC
1/10 2019 16:37 Helge Larsen/PI-redaktør 8
77242 Genmab/Dara sub. - "Scott White Yes. From a commercial perspective, we believe the subcu formulation is something that's going to open up a lot of doors for us, especially in earlier lines of therapy. If you look at DARZALEX, its utilization to market, about 50% is being used in hospitals, half is being used in the community setting. With community doctors, there's a capacity issue, especially with long infusion times, especially when you're looking at line 1 and line 2 patients".
Fra Genmabchatten d. 1. oktober 2019 med tak til Solsen
Fra Genmabchatten d. 1. oktober 2019 med tak til Solsen
